Jci_page_head_homepage_01 Jci_page_head_homepage_02
Caroline Cheng, Dennie Tempel, Rien van Haperen, Hetty C. de Boer, Dolf Segers, Martin Huisman, Anton Jan van Zonneveld, Pieter J.M. Leenen, Anton van der Steen, Patrick W. Serruys, Rini de Crom, Rob Krams
Published in Volume 117, Issue 3
J Clin Invest. 2007; 117(3):616–626 doi:10.1172/JCI28180
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
The effect of fractalkine inhibition on cap thickness and the size of the necrotic core in the LSS and OSS lesions.

Quantification of cap thickness (left) and the necrotic core (right) relative to total intimal area of the LSS and the OSS regions, comparing the control antibody group with the anti-fractalkine antibody group. n = 8. *P < 0.05 versus LSS without antibody treatment.